Drugs / Dacarbacine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06919679 | Aug 2025 → Jan 2028 expected | Hodgkins lymphoma | University of Cologne | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03042429 Comparator | Jan 2007 → Dec 2016 | neuroblastoma | University of Cologne | Completed | Met primary |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dacarbacine | “Brentuximab Vedotin Etoposide Cyclophosphamide Doxorubicin Dacarbacine Dexamethasone” NCT06919679 ↗1“cisplatin, vindesine, ifosfamide, dacarbacine, doxorubicine” NCT03042429 ↗ |